Surface grafting of Fc-binding peptides as a simple platform to immobilize and identify antibodies that selectively capture circulating endothelial progenitor cells

Bashth, Omar; Elkhodiry, Mohamed A; Laroche, Gaétan; Hoesli, Corinne A.

doi:10.1039/d0bm00650e

Cited by 10 publications

(6 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We have recently shown that antibodies immobilized through surface-grafted RRGW peptides designed to interact with the Fc region of IgG2a antibodies can selectively capture ECFCs from a mixture of cells under dynamic flow conditions [ 23 ]. A major obstacle hampering the use of protein G on implanted biomaterials such as stents is its unknown immunogenic profile and the possibility that it can provoke undesirable host immune responses [ 48 ].…”

Section: Discussionmentioning

confidence: 99%

“…More recently, improved bio-affinity-based antibody immobilization techniques emerged as an alternative that can enhance the potential of next-generation ECFC-capture stents [22][23][24]. Li et al demonstrated that stent surfaces modified with anti-CD34 antibodies immobilized via the Fc-binding protein A improved in vivo stent endothelialization compared to unmodified controls [25].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Bioaffinity-based surface immobilization of antibodies to capture endothelial colony-forming cells

et al. 2022

Self Cite

View full text Add to dashboard Cite

Maximizing the re-endothelialization of vascular implants such as prostheses or stents has the potential to significantly improve their long-term performance. Endothelial progenitor cell capture stents with surface-immobilized antibodies show significantly improved endothelialization in the clinic. However, most current antibody-based stent surface modification strategies rely on antibody adsorption or direct conjugation via amino or carboxyl groups which leads to poor control over antibody surface concentration and/or molecular orientation, and ultimately bioavailability for cell capture. Here, we assess the utility of a bioaffinity-based surface modification strategy to immobilize antibodies targeting endothelial cell surface antigens. A cysteine-tagged truncated protein G polypeptide containing three Fc-binding domains was conjugated onto aminated polystyrene substrates via a bi-functional linking arm, followed by antibody immobilization. Different IgG antibodies were successfully immobilized on the protein G-modified surfaces. Covalent grafting of the protein G polypeptide was more effective than surface adsorption in immobilizing antibodies at high density based on fluorophore-labeled secondary antibody detection, as well as endothelial colony-forming cell capture through anti-CD144 antibodies. This work presents a potential avenue for enhancing the performance of cell capture strategies by using covalent grafting of protein G polypeptides to immobilize IgG antibodies.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Bioaffinity-based surface immobilization of antibodies to capture endothelial colony-forming cells

et al. 2022

Self Cite

View full text Add to dashboard Cite

show abstract

“…We have recently shown that antibodies immobilized through the Fc region by surface conjugated RRGW can selectively capture ECFCs from a mixture of cells under dynamic flow conditions 20 . A major obstacle hampering the use of protein G on implanted biomaterials such as stents is its unknown immunogenic profile and the possibility that it can provoke undesirable host immune responses 37 .…”

Section: Discussionmentioning

confidence: 99%

“…More recently, improved bio-affinity-based antibody immobilization techniques emerged as an alternative that can enhance the potential of a new generation of ECFC-capturing stents [19][20][21] . Li et al…”

Section: Introductionmentioning

confidence: 99%

Bioaffinity-based surface-immobilization of antibodies to capture endothelial colony-forming cells

Boulanger

Elkhodiry

Bashth

et al. 2021

Preprint

Self Cite

View full text Add to dashboard Cite

Maximizing the re-endothelialization of vascular implants such as prostheses or stents has the potential to significantly improve their long-term performance. Endothelial progenitor cell capture stents with surface-immobilized antibodies show significantly improved endothelialization in the clinic. However, most current antibody-based stent surface modification strategies rely on antibody adsorption or direct conjugation via amino or carboxyl groups which leads to poor control over antibody surface concentration and/or molecular orientation, and ultimately bioavailability for cell capture. Here, we assess the utility of a bioaffinity-based surface modification strategy consisting of a surface-conjugated cysteine-tagged protein G molecules that immobilize Immunoglobulin G (IgG) antibodies via the Fc domain to capture circulating endothelial colony-forming cells (ECFCs). The cysteine-tagged protein G was grafted onto aminated substrates at different concentrations as detected by an enzyme-linked immunosorbent assay and fluorescence imaging. Different IgG antibodies were successfully immobilized on the protein G-modified surfaces and higher antibody surface concentrations were achieved compared to passive adsorption methods. Surfaces with immobilized antibodies targeting endothelial surface proteins, such as CD144, significantly enhanced the capture of circulating ECFCs in vitro compared to surfaces with non-endothelial specific antibodies such as anti-CD14. This work presents a potential avenue for enhancing the clinical performance of vascular implants by using covalent grafting of protein G to immobilize IgG antibodies more effectively.

show abstract

“…More biomarkers of EPCs have emerged in this research field, touching upon CD34, 345 CD133, 346 vascular endothelial-cadherin (VE-cadherin), 347 CD146, 344 endoglin, 348 vascular endothelial growth factor type 2 receptor (VEGFR2), 328 CD144, and CD309. 349 Fixation of antibody for bounding these biomarkers onto materials could potently attract these cells to pathological sites. Antibody fragments scFv, single chain fragment variable binding to VEGFR2 can be utilized to guide attachment and multiplying of VEGFR2-positive cells covering circulating ECs and EPCs.…”

Section: Strategies Of Lesion-localizing Delivery For Treating Athero...mentioning

confidence: 99%

Recent advance in treatment of atherosclerosis: Key targets and plaque-positioned delivery strategies

Liu

Tan

et al. 2022

J Tissue Eng

View full text Add to dashboard Cite

Atherosclerosis, a chronic inflammatory disease of vascular wall, is a progressive pathophysiological process with lipids oxidation/depositing initiation and innate/adaptive immune responses. The coordination of multi systems covering oxidative stress, dysfunctional endothelium, diseased lipid uptake, cell apoptosis, thrombotic and pro-inflammatory responding as well as switched SMCs contributes to plaque growth. In this circumstance, inevitably, targeting these processes is considered to be effective for treating atherosclerosis. Arriving, retention and working of payload candidates mediated by targets in lesion direct ultimate therapeutic outcomes. Accumulating a series of scientific studies and clinical practice in the past decades, lesion homing delivery strategies including stent/balloon/nanoparticle-based transportation worked as the potent promotor to ensure a therapeutic effect. The objective of this review is to achieve a very brief summary about the effective therapeutic methods cooperating specifical targets and positioning-delivery strategies in atherosclerosis for better outcomes.

show abstract

Surface grafting of Fc-binding peptides as a simple platform to immobilize and identify antibodies that selectively capture circulating endothelial progenitor cells

Abstract: Antibody surface immobilization via Fc-binding peptides is a promising strategy to capture circulating cells such as endothelial progenitor cells.

Cited by 10 publications

References 50 publications

Bioaffinity-based surface immobilization of antibodies to capture endothelial colony-forming cells

Bioaffinity-based surface immobilization of antibodies to capture endothelial colony-forming cells

Bioaffinity-based surface-immobilization of antibodies to capture endothelial colony-forming cells

Recent advance in treatment of atherosclerosis: Key targets and plaque-positioned delivery strategies

Contact Info

Product

Resources

About